ASH 2021 | Myeloma highlights at ASH 2021
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, shares his key takeaways in multiple myeloma from the ASH 2021 annual congress. Firstly, Dr Fonseca highlights important findings from population-based studies looking at the prevalence of smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS). The initial report of the PROMISE study (NCT03689595) was also be presented, in which high-risk individuals were screened for precursor conditions to myeloma and monitored to identify risk factors for progression to symptomatic multiple myeloma. Data on bispecific antibodies is another hot topic at the meeting highlighted by Dr Fonseca. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
